ELANCO ANIMAL HEALTH Investors Given Chance to Pursue Securities Fraud Lawsuit with Schall Law Firm
October 23, 2024
🌧️Trending News
ELANCO ANIMAL HEALTH ($NYSE:ELAN) is a leading animal health company that focuses on developing, manufacturing, and marketing products for the health and wellbeing of animals. Their stocks have been a popular choice among investors, but recent events have caused concern and potential financial losses for shareholders. That is why the Schall Law Firm, a nationally recognized shareholder rights litigation firm, is offering ELANCO investors the chance to take the lead in a securities fraud lawsuit against the company. This opportunity allows investors to seek justice for any potential securities fraud committed by ELANCO. The lawsuit claims that ELANCO failed to disclose important information about the acquisition, causing significant losses for investors. As a shareholder of ELANCO, you have a right to hold the company accountable for any potential misconduct that may have caused harm to your investments.
The Schall Law Firm is dedicated to fighting for the rights of shareholders and seeking justice for any wrongdoing by corporations. If you have suffered financial losses as a result of investing in ELANCO stocks, now is your chance to take action. The experienced team at the Schall Law Firm will guide you through the legal process and work diligently to secure a favorable outcome for you. Contact us today to learn more about how you can be a part of the securities fraud lawsuit against ELANCO and potentially recover your losses.
Market Price
This comes after the company’s stock opened at $12.46 and closed at $12.65, showing a slight increase of 0.24% from the previous closing price of $12.62. The investigation focuses on whether the company made false and misleading statements or failed to disclose important information to investors during this time period. ELANCO ANIMAL HEALTH stated that the termination was due to antitrust concerns raised by the Federal Trade Commission (FTC).
However, it has been alleged that the company failed to disclose these concerns to investors and instead continued to assure them that the acquisition was on track. They believe that ELANCO ANIMAL HEALTH may have violated federal securities laws and are determined to hold the company accountable for any potential wrongdoing. Investors who have purchased ELANCO ANIMAL HEALTH securities during the specified time period and have suffered losses are urged to contact the Schall Law Firm for more information on how to participate in the lawsuit. The firm has a track record of successfully recovering damages for investors in similar cases and is dedicated to fighting for the rights of shareholders. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for ELAN. More…
| Total Revenues | Net Income | Net Margin |
| 4.42k | -1.23k | -7.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for ELAN. More…
| Operations | Investing | Financing |
| 271 | -169 | -83 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for ELAN. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 14.36k | 8.14k | 12.63 |
Key Ratios Snapshot
Some of the financial key ratios for ELAN are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.5% | 1.2% | -20.8% |
| FCF Margin | ROE | ROA |
| 2.6% | -9.3% | -4.0% |
Analysis
After conducting a thorough analysis of ELANCO ANIMAL HEALTH’s financials, I have determined that the company has an intermediate health score of 6/10. This score takes into consideration the company’s cashflows and debt, and suggests that ELANCO ANIMAL HEALTH may be able to sustain future operations even in times of crisis. In terms of specific areas, ELANCO ANIMAL HEALTH appears to be strong in industry, medium in growth and profitability, and weak in asset and dividend categories. This indicates that the company may not have significant assets or a strong dividend yield, but it does have a stable industry and is experiencing moderate growth and profitability. Based on this analysis, I would classify ELANCO ANIMAL HEALTH as a ‘rhino’ company. This type of company is typically characterized by moderate revenue or earnings growth. This means that while ELANCO ANIMAL HEALTH may not see explosive growth, it has shown steady performance and could be considered a reliable investment opportunity. In terms of potential investors, ‘rhino’ companies like ELANCO ANIMAL HEALTH may be of interest to those seeking moderate, stable growth in their portfolio. It may also appeal to investors who are looking for companies with a strong footing in a specific industry, as ELANCO ANIMAL HEALTH seems to have a stable position within the animal health sector. Overall, while ELANCO ANIMAL HEALTH may not be the most exciting or high-growth company on the market, its financial analysis suggests that it may be a solid choice for investors seeking stability and moderate returns. As always, it is important for investors to conduct their own research and carefully consider their own investment goals before making any decisions. More…
Peers
The company’s competitors include GeneFerm Biotechnology Co Ltd, Rhone Ma Holdings Bhd, and Phibro Animal Health Corp.
– GeneFerm Biotechnology Co Ltd ($TPEX:1796)
Ferm Biotechnology Co Ltd is a company that manufactures and sells biotechnology products. The company has a market cap of 2.34B as of 2022 and a return on equity of 9.05%. The company’s products are used in the healthcare, food and beverage, and industrial markets.
– Rhone Ma Holdings Bhd ($KLSE:5278)
Rhone Ma Holdings Bhd is a Malaysia-based investment holding company. The Company, through its subsidiaries, is engaged in the provision of management services, banking and financial services, and investment holding. The Company’s segments include Commercial Banking, which is engaged in the provision of banking products and services to small and medium enterprises (SMEs) and individuals; Treasury, which is engaged in the provision of foreign exchange and money market services; and Corporate Banking, which is engaged in the provision of financing solutions to SMEs and large corporations.
– Phibro Animal Health Corp ($NASDAQ:PAHC)
Phibro Animal Health Corp is a publicly traded company that focuses on animal health and nutrition. As of 2022, the company had a market capitalization of 505.49 million and a return on equity of 19.25%. Phibro Animal Health Corp was founded in 1947 and is headquartered in Teaneck, New Jersey. The company’s products include pharmaceuticals, vaccines, and nutritional supplements for livestock, poultry, and aquaculture.
Summary
ELANCO ANIMAL HEALTH has been facing a potential securities fraud lawsuit, giving investors the opportunity to lead the case with the Schall Law Firm. This could potentially result in financial losses for the company and affect its stock performance. Investors should closely monitor any developments in this case and consider the potential impact on their investments.
Additionally, it is important to stay updated on the company’s financial performance and any regulatory changes that could affect the animal health industry. Careful analysis and research can help investors make informed decisions about investing in ELANCO ANIMAL HEALTH.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
